[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Septerna Inc (SEPN)

Septerna Inc (SEPN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,556,925
  • Shares Outstanding, K 45,076
  • Annual Sales, $ 45,950 K
  • Annual Income, $ -48,880 K
  • EBIT $ -56 M
  • EBITDA $ -54 M
  • 60-Month Beta 2.29
  • Price/Sales 33.71
  • Price/Cash Flow N/A
  • Price/Book 4.08

Options Overview Details

View History
  • Implied Volatility 96.58% (+6.06%)
  • Historical Volatility 64.39%
  • IV Percentile 93%
  • IV Rank 63.64%
  • IV High 119.88% on 11/07/25
  • IV Low 55.79% on 05/15/26
  • Expected Move (DTE 1) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.05
  • Today's Volume 79
  • Volume Avg (30-Day) 371
  • Put/Call OI Ratio 0.43
  • Today's Open Interest 14,876
  • Open Int (30-Day) 15,076
  • Expected Range 34.07 to 34.07

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.48
  • Number of Estimates 4
  • High Estimate $-0.16
  • Low Estimate $-0.82
  • Prior Year $-0.56
  • Growth Rate Est. (year over year) +14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.00 +6.47%
on 06/29/26
38.04 -10.44%
on 07/09/26
-1.96 (-5.44%)
since 06/15/26
3-Month
22.78 +49.56%
on 04/29/26
38.04 -10.44%
on 07/09/26
+8.14 (+31.39%)
since 04/15/26
52-Week
10.62 +220.93%
on 08/12/25
38.04 -10.44%
on 07/09/26
+22.40 (+191.95%)
since 07/15/25

Most Recent Stories

More News
Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting

Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that the first detailed preclinical characterization...

SEPN : 34.07 (-1.36%)
Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results

 Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026 Phase 1 Clinical...

SEPN : 34.07 (-1.36%)
Septerna to Present at Bank of America Securities Health Care Conference

SOUTH SAN FRANCISCO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery,...

SEPN : 34.07 (-1.36%)
Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism

Trial Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SEP-479 in Healthy Volunteers Data Anticipated in Late 2026 or Early 2027 SOUTH SAN FRANCISCO, Calif.,...

SEPN : 34.07 (-1.36%)
Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results

Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026  Advancing SEP-479...

SEPN : 34.07 (-1.36%)
Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy

SEP-631 Demonstrated Robust, Dose-Dependent Inhibition of Icatibant-Induced Skin Wheal Formation, with Complete Inhibition Observed at Doses as Low as 10 mg Once-Daily  Well-Tolerated Across All...

SEPN : 34.07 (-1.36%)
Septerna to Present at TD Cowen 46th Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery,...

SEPN : 34.07 (-1.36%)
Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery,...

SEPN : 34.07 (-1.36%)
Septerna to Present Data from Phase 1 Clinical Trial of SEP-631 for the Treatment of Mast Cell-Driven Diseases at 2026 AAAAI Annual Meeting

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery,...

SEPN : 34.07 (-1.36%)
Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer

SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery,...

SEPN : 34.07 (-1.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Septerna Inc. is a clinical-stage biotechnology company pioneering a new era of GPCR oral small molecule drug discovery powered by its proprietary Native Complex Platform(TM). Septerna Inc. is based in SOUTH SAN FRANCISCO, Calif.

See More

Key Turning Points

3rd Resistance Point 38.37
2nd Resistance Point 36.82
1st Resistance Point 35.44
Last Price 34.07
1st Support Level 32.51
2nd Support Level 30.96
3rd Support Level 29.58

See More

52-Week High 38.04
Last Price 34.07
Fibonacci 61.8% 27.56
Fibonacci 50% 24.33
Fibonacci 38.2% 21.09
52-Week Low 10.62

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.